Omeros Corporation (OMER) Shares Up -4.5%

Omeros Corporation (NASDAQ:OMER)’s share price shot up 4.5% on Friday . The company traded as high as $15.30 and last traded at $14.70. 643,419 shares were traded during trading, a decline of 31% from the average session volume of 930,038 shares. The stock had previously closed at $15.39.

A number of research firms have weighed in on OMER. Cowen and Company lowered Omeros Corporation from an “outperform” rating to a “market perform” rating in a research note on Thursday. Maxim Group set a $24.00 price objective on Omeros Corporation and gave the company a “buy” rating in a research note on Wednesday, August 2nd. Wedbush reiterated an “outperform” rating and set a $47.00 price objective on shares of Omeros Corporation in a research note on Friday, August 18th. Zacks Investment Research upgraded Omeros Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $19.00 price objective (up previously from $15.00) on shares of Omeros Corporation in a research note on Thursday, August 24th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $34.83.

The company has a debt-to-equity ratio of -1.49, a quick ratio of 2.11 and a current ratio of 2.15.

Omeros Corporation (NASDAQ:OMER) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.12. The business had revenue of $17.15 million for the quarter, compared to analyst estimates of $14.63 million. During the same quarter last year, the business earned ($0.32) earnings per share. Omeros Corporation’s revenue was up 71.5% on a year-over-year basis. equities research analysts predict that Omeros Corporation will post -1.32 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Legal & General Group Plc grew its position in shares of Omeros Corporation by 7.8% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 751 shares during the period. Russell Investments Group Ltd. acquired a new stake in Omeros Corporation in the 1st quarter worth about $292,000. Voya Investment Management LLC boosted its holdings in Omeros Corporation by 20.7% in the 2nd quarter. Voya Investment Management LLC now owns 19,300 shares of the biopharmaceutical company’s stock worth $384,000 after buying an additional 3,304 shares during the last quarter. Highbridge Capital Management LLC acquired a new stake in Omeros Corporation in the 1st quarter worth about $330,000. Finally, Mesirow Financial Investment Management Inc. acquired a new stake in Omeros Corporation in the 2nd quarter worth about $456,000. Hedge funds and other institutional investors own 44.91% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Omeros Corporation (OMER) Shares Up -4.5%” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at

About Omeros Corporation

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

What are top analysts saying about Omeros Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omeros Corporation and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit